PP405Q4 2025 update: Pelage Pharmaceuticals & PP405
What’s happening with the trials: despite chatter online about an active Phase 2B, public company updates and press coverage point to a Phase 2a program with an extension for some participants that runs through around December 2025; there is no clear, registered Phase 2b study currently visible in Pelage’s filings or major reports.
Grey market copies and chemical names: several vendors and community posts list JXL-069 as the compound likely linked to PP405, and research-chemical shops openly sell JXL-069 as “for lab use only.” reports and forum threads also call out a related prodrug, JXL-082, but community testing and seller notes suggest these are not delivering the PP405 effect in practice. in short, marketed knockoffs exist, yet they don't appear to reproduce the clinical signal.
